Dechra Pharmaceuticals plc (DPH) Given Average Rating of “Buy” by Analysts
Dechra Pharmaceuticals plc (LON:DPH) has been given an average rating of “Buy” by the eight research firms that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is GBX 1,784 ($24.01).
Separately, Jefferies Group raised their price target on Dechra Pharmaceuticals from GBX 1,565 ($21.06) to GBX 1,868 ($25.14) and gave the stock a “hold” rating in a report on Tuesday, September 5th.
In related news, insider Ian Page sold 54,910 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of GBX 2,024 ($27.24), for a total value of £1,111,378.40 ($1,495,798.65).
About Dechra Pharmaceuticals
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.
Receive News & Ratings for Dechra Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals plc and related companies with MarketBeat.com's FREE daily email newsletter.